.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Molecular engineering has enabled the creation of advanced NIR-II phototheranostic agents for precise cancer management. Researchers recently developed a novel ionic small-molecule agent called 2PyI. By carefully balancing positive charges and hydrophilicity, they achieved an optimal amphiphilic structure. Consequently, this innovation allows for high-resolution imaging and powerful therapeutic effects.
The 2PyI agent provides several critical functions within a single molecule. First, it enables efficient NIR-II emission, which is essential for deep-tissue imaging. Furthermore, it produces reactive oxygen species to destroy malignant cells. It also facilitates photothermal conversion to generate localized heat. Therefore, this synergistic approach enhances the efficacy of both photodynamic and photothermal therapies.
In addition to its therapeutic power, the high-resolution imaging guides clinicians during treatment. Traditional imaging methods often struggle with deep-seated tumors. However, NIR-II light penetrates biological tissues much more effectively than visible light. Because of this, the new agent offers a promising platform for image-guided oncology. Ultimately, such molecular engineering paves the way for more effective and less invasive cancer treatments.
NIR-II imaging uses the second near-infrared window to provide deep tissue penetration and high resolution. This allows doctors to locate tumors more accurately than with conventional imaging.
It combines photodynamic therapy, which uses light to create reactive oxygen species, with photothermal therapy, which generates heat. Together, they provide a more potent effect against cancer cells.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Gong J et al. Molecular engineering of ionic organic phototheranostic agents for NIR-II imaging-guided synergistic phototherapy. Chem Commun (Camb). 2026 Feb 23. doi: 10.1039/d6cc00306k. PMID: 41725580.
Zhang X, et al. Recent advances in near-infrared-II (NIR-II) small molecule fluorophores for cancer theranostics. Journal of Materials Chemistry B. 2025.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers develop 2PyI, an ionic small-molecule agent for high-resolution NIR-II imaging and synergistic photodynamic/photothermal therapy....
8 months ago
Novel diimide and hydrazone scaffolds, particularly compound #C4, synergistically reactivate latent HIV-1 when combined with JQ1 or PKC activators. Demonstrating donor-matched proviral transcription ex vivo and non-canonical signaling, these findings advance shock and kill strategies toward reservoir eradication.
Today
A cross-sectional study reveals that maternal RSV vaccination coverage reached only 43.7% in Argentina, with maternal vaccine knowledge being the sole independent predictor of uptake. Clinicians play a crucial role in eliminating informational and structural barriers to optimize infant health.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday
